Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neural TherapeuticsNURLF Operating Cash Flow per Share is $-0.00 as of Jan. 2026. The stock has 1 warning sign investors should review. Among 1,130 Biotechnology companies, Neural Therapeutics ranks better than 50.27% on this metric.
Neural Therapeutics's operating cash flow per share for the
three
months ended in Jan. 2026 was $0.00.
Neural Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Jan. 2026 was $-0.00.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 17.00% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -39.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Neural Therapeutics's Operating Cash Flow per Share or its related term are showing as below:
NURLF'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -81.7 Med: -71 Max: 17
Current: 17
During the past 6 years, Neural Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 17.00% per year. The lowest was -81.70% per year. And the median was -71.00% per year.
NURLF's 3-Year OCF Growth Rate is ranked better than 50.27% of 1130
companies
in the Biotechnology industry
Industry Median: 16.85
vs NURLF: 17.00
Neural Therapeutics Operating Cash Flow per Share Related Terms
Neural Therapeutics Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Neural Therapeutics's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neural Therapeutics Operating Cash Flow per Share Chart
NURLF vs VRTX, REGN, MRNA: Operating Cash Flow per Share Comparison
For the Biotechnology subindustry, Neural Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neural Therapeutics Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neural Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Neural Therapeutics's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $-0.00 mean?
Neural Therapeutics (NURLF) has a Operating Cash Flow per Share of $-0.00 as of Jan. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Neural Therapeutics and its competitors. According to the industry distribution chart, Neural Therapeutics ranks #562 out of 1130 companies in the Biotechnology industry, placing it in the top 49.7%.
Is Neural Therapeutics' Operating Cash Flow per Share too high?
Neural Therapeutics' current Operating Cash Flow per Share is $-0.00. Based on the distribution chart, Neural Therapeutics ranks #562 out of 1130 companies in the Biotechnology industry, which is above the industry midpoint.
How does Neural Therapeutics' Operating Cash Flow per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neural Therapeutics ranks #562 out of 1130 companies for Operating Cash Flow per Share. This puts Neural Therapeutics in the upper half of its industry. The industry median Operating Cash Flow per Share is 16.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Biotechnology company?
The median Operating Cash Flow per Share among Biotechnology companies is 16.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Neural Therapeutics and its competitors. For the Biotechnology industry, the median Operating Cash Flow per Share is 16.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neural Therapeutics's current Operating Cash Flow per Share is $-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (NURLF) has a current Operating Cash Flow per Share of $-0.00. The current Operating Cash Flow per Share is $-0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Neural Therapeutics (NURLF), the current Operating Cash Flow per Share is $-0.00 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NURLF has been successfully added to your 
